Literature DB >> 16880183

Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?

Henri Boulanger1, Rafik Mansouri, Jean François Gautier, Denis Glotz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16880183     DOI： 10.1093/ndt/gfl448

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  4 in total

1.  Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1.

Authors:  Qing Qing Wu; Yanxia Wang; Martin Senitko; Colin Meyer; W Christian Wigley; Deborah A Ferguson; Eric Grossman; Jianlin Chen; Xin J Zhou; John Hartono; Pamela Winterberg; Bo Chen; Anapam Agarwal; Christopher Y Lu
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-02

2.  The subtypes of peroxisome proliferator-activated receptors expressed by human podocytes and their role in decreasing podocyte injury.

Authors:  Gianluca Miglio; Arianna Carolina Rosa; Lorenza Rattazzi; Cristina Grange; Massimo Collino; Giovanni Camussi; Roberto Fantozzi
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

3.  Effect of clofibrate on fatty acid metabolism in the kidney of puromycin-induced nephrotic rats.

Authors:  Yoshikazu Muroya; Osamu Ito
Journal:  Clin Exp Nephrol       Date:  2016-03-07       Impact factor: 2.801

4.  Nuclear hormone receptors in podocytes.

Authors:  Simran Khurana; Leslie A Bruggeman; Hung-Ying Kao
Journal:  Cell Biosci       Date:  2012-09-20       Impact factor: 7.133
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.